Orphan Drugs
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
April 22, 2026
Soligenix Receives FDA Orphan Drug Designation for Dusquetide in Behçet's Disease Treatment
Soligenix Inc. has secured FDA orphan drug designation for its investigational therapy dusquetide, marking a significant advancement in treating Behçet's disease following promising phase 2a clinical trial results.
September 4, 2025
ReAlta Life Sciences Gains EMA Orphan Drug Designation for Graft-Versus-Host Disease Treatment
ReAlta Life Sciences received European Medicines Agency Orphan Drug Designation for its drug pegtarazimod, advancing a novel dual-targeting treatment approach for steroid-refractory acute graft-versus-host disease that addresses critical unmet medical needs.
August 21, 2025